The first dominant SARS‐CoV‐2 Omicron variant BA. 1 harbours 35 mutations in its Spike
protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its …

Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …

Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …

Objectives To characterize the clinical severity of covid-19 associated with the alpha, delta,
and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the …

Genomic surveillance has shaped our understanding of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) variants. We performed a global landscape analysis on SARS …

Abstract SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants are genetically divergent. We
conducted a matched, test-negative, case-control study to estimate duration of protection of …

Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and
the emergence of the omicron (or B. 1.1. 529) variant of the severe acute respiratory …

Background Waning of vaccine protection against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern …

Where 2020 saw the development and testing of vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has …

Background The protection conferred by natural immunity, vaccination, and both against
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with …